Merck is spending this year converting pembrolizumab cash into a second commercial stack before intravenous exclusivity thins later this decade. The Rahway company is no longer asking investors to take that claim on faith. The June quarter is the first stretch where launch products, a subcutaneous sibling, and a newly approved oral cholesterol medicine sit on the same page as a still-dominant oncology franchise. Worldwide sales reached $16.6 billion. Growth of 5% arrived while diabetes products rolled off patent and while two cash acquisitions hit the income statement as research charges.
The franchise still supplies about half of company sales. The subcutaneous formulation booked $463 million after a permanent billing code landed in April. WINREVAIR, the pulmonary arterial hypertension launch, grew 75%. That combination is the replacement engine the equity actually needs to see compound, not merely debut. The bear case answers that the Terns charge, stacked on an earlier Cidara charge, turned reported earnings into a loss and that headline growth still leans on one oncology family. Looking through the charges is reasonable. Pretending the concentration risk has already been solved is not.
Management lifted the sales outlook into a band around $67 billion and cut the earnings outlook because deal charges now sit inside the guide. The debate is whether the launch cohort plus pipeline derisking replace enough of the oncology cash engine before biosimilars arrive, or whether the multiple already assumes a hill that is still a cliff. Mix inside the pembrolizumab family, persistence on WINREVAIR, and early LIPFENDRA prescriptions are what settle that argument.